NASDAQ:IMNM

Immunome Competitors

$27.83
-1.88 (-6.33 %)
(As of 04/14/2021 04:52 PM ET)
Add
Compare
Today's Range
$27.55
Now: $27.83
$30.10
50-Day Range
$28.51
MA: $32.68
$43.24
52-Week Range
$9.27
Now: $27.83
$63.78
Volume78,646 shs
Average Volume264,759 shs
Market Capitalization$296.67 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Immunome (NASDAQ:IMNM) Vs. STOK, OCUL, PHAT, RPTX, INVA, and PRAX

Should you be buying IMNM stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Immunome, including Stoke Therapeutics (STOK), Ocular Therapeutix (OCUL), Phathom Pharmaceuticals (PHAT), Repare Therapeutics (RPTX), Innoviva (INVA), and Praxis Precision Medicines (PRAX).

Immunome (NASDAQ:IMNM) and Stoke Therapeutics (NASDAQ:STOK) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, risk, dividends and profitability.

Earnings and Valuation

This table compares Immunome and Stoke Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunomeN/AN/A$-10,440,000.00N/AN/A
Stoke TherapeuticsN/AN/A$-32,330,000.00($1.80)-19.06

Profitability

This table compares Immunome and Stoke Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ImmunomeN/AN/AN/A
Stoke TherapeuticsN/A-22.93%-22.26%

Analyst Ratings

This is a breakdown of current ratings for Immunome and Stoke Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Immunome00203.00
Stoke Therapeutics02602.75

Immunome presently has a consensus price target of $18.00, indicating a potential downside of 35.32%. Stoke Therapeutics has a consensus price target of $64.3333, indicating a potential upside of 87.72%. Given Stoke Therapeutics' higher probable upside, analysts clearly believe Stoke Therapeutics is more favorable than Immunome.

Summary

Immunome beats Stoke Therapeutics on 4 of the 6 factors compared between the two stocks.

Immunome (NASDAQ:IMNM) and Ocular Therapeutix (NASDAQ:OCUL) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, risk, dividends and profitability.

Insider and Institutional Ownership

52.5% of Ocular Therapeutix shares are held by institutional investors. 7.7% of Ocular Therapeutix shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Immunome and Ocular Therapeutix's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ImmunomeN/AN/AN/A
Ocular Therapeutix-780.19%-14,065.71%-81.81%

Analyst Ratings

This is a breakdown of current ratings for Immunome and Ocular Therapeutix, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Immunome00203.00
Ocular Therapeutix01213.00

Immunome presently has a consensus price target of $18.00, indicating a potential downside of 35.32%. Ocular Therapeutix has a consensus price target of $24.80, indicating a potential upside of 50.30%. Given Ocular Therapeutix's higher probable upside, analysts clearly believe Ocular Therapeutix is more favorable than Immunome.

Earnings and Valuation

This table compares Immunome and Ocular Therapeutix's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunomeN/AN/A$-10,440,000.00N/AN/A
Ocular Therapeutix$4.23 million296.73$-86,370,000.00($2.01)-8.21

Immunome has higher earnings, but lower revenue than Ocular Therapeutix.

Summary

Ocular Therapeutix beats Immunome on 5 of the 9 factors compared between the two stocks.

Phathom Pharmaceuticals (NASDAQ:PHAT) and Immunome (NASDAQ:IMNM) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, risk, analyst recommendations, earnings and institutional ownership.

Insider and Institutional Ownership

73.8% of Phathom Pharmaceuticals shares are held by institutional investors. 39.8% of Phathom Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Phathom Pharmaceuticals and Immunome's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Phathom PharmaceuticalsN/A-88.73%-69.04%
ImmunomeN/AN/AN/A

Analyst Recommendations

This is a summary of recent recommendations and price targets for Phathom Pharmaceuticals and Immunome, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Phathom Pharmaceuticals10402.60
Immunome00203.00

Phathom Pharmaceuticals currently has a consensus target price of $53.00, indicating a potential upside of 39.03%. Immunome has a consensus target price of $18.00, indicating a potential downside of 35.32%. Given Phathom Pharmaceuticals' higher probable upside, analysts plainly believe Phathom Pharmaceuticals is more favorable than Immunome.

Valuation & Earnings

This table compares Phathom Pharmaceuticals and Immunome's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Phathom PharmaceuticalsN/AN/A$-255,130,000.00($13.98)-2.74
ImmunomeN/AN/A$-10,440,000.00N/AN/A

Repare Therapeutics (NASDAQ:RPTX) and Immunome (NASDAQ:IMNM) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, risk, analyst recommendations, earnings and institutional ownership.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Repare Therapeutics and Immunome, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Repare Therapeutics01513.00
Immunome00203.00

Repare Therapeutics currently has a consensus target price of $39.40, indicating a potential upside of 15.07%. Immunome has a consensus target price of $18.00, indicating a potential downside of 35.32%. Given Repare Therapeutics' higher probable upside, analysts plainly believe Repare Therapeutics is more favorable than Immunome.

Valuation & Earnings

This table compares Repare Therapeutics and Immunome's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Repare TherapeuticsN/AN/AN/AN/AN/A
ImmunomeN/AN/A$-10,440,000.00N/AN/A

Profitability

This table compares Repare Therapeutics and Immunome's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Repare TherapeuticsN/AN/AN/A
ImmunomeN/AN/AN/A

Insider and Institutional Ownership

64.8% of Repare Therapeutics shares are held by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Repare Therapeutics beats Immunome on 4 of the 4 factors compared between the two stocks.

Immunome (NASDAQ:IMNM) and Innoviva (NASDAQ:INVA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, analyst recommendations, earnings and institutional ownership.

Analyst Ratings

This is a summary of recent ratings and price targets for Immunome and Innoviva, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Immunome00203.00
Innoviva10001.00

Immunome currently has a consensus target price of $18.00, indicating a potential downside of 35.32%. Innoviva has a consensus target price of $10.00, indicating a potential downside of 14.89%. Given Innoviva's higher probable upside, analysts plainly believe Innoviva is more favorable than Immunome.

Earnings and Valuation

This table compares Immunome and Innoviva's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunomeN/AN/A$-10,440,000.00N/AN/A
Innoviva$261.02 million4.56$157.29 million$1.438.22

Innoviva has higher revenue and earnings than Immunome.

Profitability

This table compares Immunome and Innoviva's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ImmunomeN/AN/AN/A
Innoviva67.16%53.99%28.92%

Insider & Institutional Ownership

71.5% of Innoviva shares are held by institutional investors. 0.3% of Innoviva shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Innoviva beats Immunome on 8 of the 10 factors compared between the two stocks.

Immunome (NASDAQ:IMNM) and Praxis Precision Medicines (NASDAQ:PRAX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, analyst recommendations, earnings and institutional ownership.

Analyst Ratings

This is a summary of recent ratings and price targets for Immunome and Praxis Precision Medicines, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Immunome00203.00
Praxis Precision Medicines00403.00

Immunome currently has a consensus target price of $18.00, indicating a potential downside of 35.32%. Praxis Precision Medicines has a consensus target price of $60.3333, indicating a potential upside of 138.47%. Given Praxis Precision Medicines' higher probable upside, analysts plainly believe Praxis Precision Medicines is more favorable than Immunome.

Earnings and Valuation

This table compares Immunome and Praxis Precision Medicines' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunomeN/AN/A$-10,440,000.00N/AN/A
Praxis Precision MedicinesN/AN/AN/AN/AN/A

Profitability

This table compares Immunome and Praxis Precision Medicines' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ImmunomeN/AN/AN/A
Praxis Precision MedicinesN/AN/AN/A

Summary

Praxis Precision Medicines beats Immunome on 2 of the 2 factors compared between the two stocks.


Immunome Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.4$34.31-3.6%$1.21 billionN/A-19.06
Ocular Therapeutix logo
OCUL
Ocular Therapeutix
1.6$16.50-3.7%$1.21 billion$4.23 million-9.22News Coverage
Gap Down
Phathom Pharmaceuticals logo
PHAT
Phathom Pharmaceuticals
1.8$38.35-1.6%$1.20 billionN/A-2.74Gap Down
Repare Therapeutics logo
RPTX
Repare Therapeutics
1.6$34.24-5.3%$1.20 billionN/A0.00
Innoviva logo
INVA
Innoviva
1.4$11.75-1.0%$1.19 billion$261.02 million5.99
Praxis Precision Medicines logo
PRAX
Praxis Precision Medicines
1.7$25.30-20.0%$1.17 billionN/A0.00Increase in Short Interest
Lockup Expiration
Avid Bioservices logo
CDMO
Avid Bioservices
1.7$19.23-0.1%$1.17 billion$59.70 million-192.30
NKTX
Nkarta
1.8$35.98-1.2%$1.17 billionN/A0.00Increase in Short Interest
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$10.14-1.8%$1.15 billion$35.22 million-7.40
Protagonist Therapeutics logo
PTGX
Protagonist Therapeutics
1.5$25.99-1.6%$1.12 billion$230,000.00-12.09News Coverage
Gap Down
Mersana Therapeutics logo
MRSN
Mersana Therapeutics
1.2$17.14-5.7%$1.12 billion$42.12 million-12.70Unusual Options Activity
News Coverage
Y-mAbs Therapeutics logo
YMAB
Y-mAbs Therapeutics
1.6$26.79-4.5%$1.11 billionN/A-9.02Increase in Short Interest
Constellation Pharmaceuticals logo
CNST
Constellation Pharmaceuticals
1.2$23.08-5.2%$1.10 billionN/A-8.52Gap Down
Omeros logo
OMER
Omeros
1.4$17.56-0.4%$1.08 billion$111.81 million-7.38
Pliant Therapeutics logo
PLRX
Pliant Therapeutics
1.9$30.23-0.1%$1.08 billion$57.05 million0.00
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.7$16.24-3.3%$1.07 billionN/A-6.85
Zogenix logo
ZGNX
Zogenix
1.7$19.43-1.7%$1.06 billion$3.65 million-2.04
Arcturus Therapeutics logo
ARCT
Arcturus Therapeutics
1.6$39.92-1.2%$1.05 billion$20.79 million-13.77Analyst Upgrade
News Coverage
MannKind logo
MNKD
MannKind
1.4$4.56-7.7%$1.05 billion$63.04 million-21.71Increase in Short Interest
Trillium Therapeutics logo
TRIL
Trillium Therapeutics
1.7$10.24-1.6%$1.04 billion$120,000.00-3.79Analyst Upgrade
News Coverage
G1 Therapeutics logo
GTHX
G1 Therapeutics
1.5$24.70-1.7%$1.04 billionN/A-8.52
Rhythm Pharmaceuticals logo
RYTM
Rhythm Pharmaceuticals
1.8$20.75-0.5%$1.04 billionN/A-6.83Increase in Short Interest
Enanta Pharmaceuticals logo
ENTA
Enanta Pharmaceuticals
1.4$50.65-2.4%$1.02 billion$122.47 million-27.83Analyst Downgrade
Syndax Pharmaceuticals logo
SNDX
Syndax Pharmaceuticals
1.6$21.68-5.0%$993.66 million$1.52 million-11.53Increase in Short Interest
Phibro Animal Health logo
PAHC
Phibro Animal Health
1.8$24.25-0.2%$982.60 million$800.40 million22.88
Prothena logo
PRTA
Prothena
2.1$23.96-2.5%$934.94 million$810,000.00-9.36Increase in Short Interest
Akero Therapeutics logo
AKRO
Akero Therapeutics
1.7$27.31-3.3%$918.28 millionN/A-12.59Analyst Upgrade
ESSA Pharma logo
EPIX
ESSA Pharma
1.4$26.64-1.7%$899.90 millionN/A-24.67
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$16.45-0.9%$895.14 million$227.19 million45.70
Radius Health logo
RDUS
Radius Health
1.3$19.67-3.9%$886.30 million$173.32 million-8.06Gap Down
Annexon logo
ANNX
Annexon
1.9$23.35-1.3%$879.54 millionN/A0.00Increase in Short Interest
Gap Down
Affimed logo
AFMD
Affimed
1.6$10.33-4.3%$873.54 million$23.96 million-17.51Analyst Report
Dyne Therapeutics logo
DYN
Dyne Therapeutics
1.6$17.16-1.5%$869.64 millionN/A0.00News Coverage
Gap Down
Merus logo
MRUS
Merus
1.6$23.22-2.5%$863.20 million$31.13 million-7.56Analyst Report
Analyst Revision
BioXcel Therapeutics logo
BTAI
BioXcel Therapeutics
1.6$34.95-1.5%$845.56 millionN/A-10.37
Epizyme logo
EPZM
Epizyme
1.8$8.22-0.4%$833.11 million$23.80 million-3.69
Amphastar Pharmaceuticals logo
AMPH
Amphastar Pharmaceuticals
1.5$17.40-0.4%$822.01 million$322.36 million124.29
Humanigen logo
HGEN
Humanigen
1.7$15.38-1.1%$813.46 millionN/A0.00Analyst Report
Increase in Short Interest
Collegium Pharmaceutical logo
COLL
Collegium Pharmaceutical
1.4$24.02-4.6%$806.52 million$296.70 million49.02Gap Down
ORIC Pharmaceuticals logo
ORIC
ORIC Pharmaceuticals
1.7$21.29-7.4%$781.24 millionN/A0.00Increase in Short Interest
Ardelyx logo
ARDX
Ardelyx
1.6$7.84-8.2%$773.65 million$5.28 million-7.76Unusual Options Activity
News Coverage
Karyopharm Therapeutics logo
KPTI
Karyopharm Therapeutics
1.7$10.20-1.0%$765.62 million$40.89 million-3.52Analyst Report
Esperion Therapeutics logo
ESPR
Esperion Therapeutics
1.4$27.15-3.5%$758.65 million$148.36 million-7.05News Coverage
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$5.19-0.2%$749.20 million$322.07 million-4.94Decrease in Short Interest
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$3.45-2.0%$727.39 million$150,000.00-4.93
VBI Vaccines logo
VBIV
VBI Vaccines
1.5$2.89-1.4%$723.91 million$2.22 million-17.00
Chimerix logo
CMRX
Chimerix
1.3$8.37-0.7%$711.99 million$12.52 million-14.68Analyst Report
Increase in Short Interest
Veru logo
VERU
Veru
1.4$9.88-0.5%$710.49 million$42.59 million-35.28Analyst Report
News Coverage
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
2.2$21.41-1.1%$698.95 million$252 million-2.19News Coverage
Bicycle Therapeutics logo
BCYC
Bicycle Therapeutics
1.3$29.96-2.2%$691.78 million$13.80 million-14.47Gap Down
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.